Tag Archives: hematology

June, 2018

20 June
TG and Novimmune Collaborate for Development of CD47-CD19 Bispecific Antibody

NEW YORK, June 20, 2018 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ:TGTX) and Novimmune SA, today announced that the companies have entered into an exclusive global agreement to collaborate on the development and commercialization of Novimmune’s novel first-in-class anti-CD47/anti-CD19 bispecific antibody known as TG-1801 (previously NI-1701). The companies will jointly develop …
Share

5 April
H3 Biomedicine’s First-in-Class Splicing Factor Modulator Shows Promise in Multiple Types of Cancer in Early-Stage Trial

CAMBRIDGE, Mass.–(BUSINESS WIRE)–H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of next-generation cancer medicines using its data science and precision chemistry product engine, announced today the publication of a comprehensive genomic landscape analysis illuminating the breadth, frequency and potential disease-driving significance of somatic mutations …
Share

14 September
Engineered Therapy for Blood Clotting Disorder Shows Early Promise

WASHINGTON, Sept. 14, 2017 /PRNewswire/ — An investigational treatment that mimics a key clotting enzyme is effective, safe, and may one day eliminate the need for blood products for people with the rare, life-threatening blood disease hereditary thrombotic thrombocytopenic purpura (TTP), according to a study published online today in Blood, …
Share

30 January
Incyte and Calithera Collaborate for Development of Clinical-Stage Arginase Inhibitor

WILMINGTON, Del. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Incyte Corporation (NASDAQ:INCY) and Calithera Biosciences, Inc. (NASDAQ:CALA) announce today that the companies have entered into a global collaboration and license agreement for the research, development and commercialization of Calithera’s first-in-class, small molecule arginase inhibitor CB-1158 in hematology and oncology. CB-1158 is currently …
Share

1 August
Jazz Enters Hematological Malignancies Licensing Deal with Pfenex

DUBLIN and SAN DIEGO, July 28, 2016 /PRNewswire/ — Jazz Pharmaceuticals plc(Nasdaq: JAZZ) and Pfenex Inc. (NYSE MKT: PFNX) today announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates. The agreement also includes an option for Jazz Pharmaceuticals …
Share

29 July
Editas Medicine Enters Collaboration with Italian Gene Therapy Institute

CAMBRIDGE, Mass., July 28, 2016 (GLOBE NEWSWIRE) — Editas Medicine, Inc.(NASDAQ:EDIT), a leading genome editing company, and Fondazione Telethon and Ospedale San Raffaele, which operate a joint research collaboration known as the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), have entered into a scientific collaboration to research and develop …
Share

7 December
Novartis Announces Positive Results for its CAR-T Therapy

Basel, December 6, 2015 – Findings from an ongoing Phase IIa study to evaluate the safety and efficacy of investigational chimeric antigen receptor T cell (CART) therapy CTL019 in certain types of relapsed or refractory (r/r) non-Hodgkin lymphoma will be presented in an oral session at the 57th American Society …
Share

23 October
FDA Declines to Approve Spectrum’s Blood Cancer Drug

HENDERSON, Nev.–(BUSINESS WIRE)–Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA). A Complete Response Letter is a communication …
Share

1 June
Baxter, Mayo Clinic and VPD Form Vitesse Biologics to Accelerate Drug Development

In an effort to accelerate therapeutic innovation, Baxter Ventures, the Mayo Clinic and Velocity Pharmaceutical Development (VPD) have teamed up to form a new company called Vitesse Biologics, LLC. The formation of Vitesse is a unique collaboration model initiated by Baxter Ventures to focus on the development of antibody and …
Share

1 May
ASH Issues Report Outlining Top Priorities for Scientific Discovery

A report issued by the American Society of Hematology (ASH) urged scientists and funding institutions to coordinate their efforts around six research areas with the greatest potential to dramatically impact the care of patients with a variety of diseases. The professional society issued the ASH Agenda for Hematology Research, a …
Share